The medication in this study is being developed as a potential new treatment for idiopathic pulmonary fibrosis (IPF), a disease that causes progressive, irreversible damage to the lungs. IPF typically affects adults over the age of 40, and the prevalence is increasing globally.
Although there is no cure for IPF and no medications that can remove the scarring to the lungs, there is a need for effective treatments to slow the progression of the condition. The medication in this study is designed to prevent the spread of the fibrosis (scarring) in IPF patients.
For the initial stage of research into this medication, we require healthy participants with no medical conditions. This is so we can look at how the body metabolises the medication. At a later stage, it is hoped the medication will go on to be tested in patients with IPF.
The trial has been approved by an independent ethics committee and you will be reimbursed for your time.